Myovant Sciences Ltd.
(NYSE : MYOV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.97%73.511.0%$1662.26m
AMGNAmgen, Inc. -0.45%218.211.3%$912.64m
REGNRegeneron Pharmaceuticals, Inc. 0.12%512.962.6%$838.70m
BIIBBiogen, Inc. 1.29%321.051.5%$803.32m
VRTXVertex Pharmaceuticals, Inc. -1.22%246.611.9%$654.46m
ILMNIllumina, Inc. 2.36%287.623.5%$500.86m
MRNAModerna, Inc. -1.73%31.860.0%$490.05m
ALXNAlexion Pharmaceuticals, Inc. -2.36%96.232.0%$302.00m
AAgilent Technologies, Inc. 2.14%78.331.6%$228.79m
INCYIncyte Corp. -1.07%86.812.5%$215.18m
EXASEXACT Sciences Corp. 1.04%67.0621.0%$180.99m
SGENSeattle Genetics, Inc. 0.54%120.326.1%$157.23m
BMRNBioMarin Pharmaceutical, Inc. -0.06%79.554.3%$148.36m
IMMUImmunomedics, Inc. 6.57%19.6411.9%$133.04m
NVAXNovavax, Inc. -0.76%17.05114.7%$128.79m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.